Fjarde Ap Fonden Pulmonx Corp Call Options Transaction History
Fjarde Ap Fonden
- $10.8 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUNG
# of Institutions
131Shares Held
33MCall Options Held
2.6KPut Options Held
216K-
Primecap Management CO Pasadena, CA5.41MShares$8.88 Million0.03% of portfolio
-
Morgan Stanley New York, NY3.49MShares$5.73 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$4.38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$3.74 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.89MShares$3.1 Million0.32% of portfolio
About Pulmonx Corp
- Ticker LUNG
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 37,268,400
- Market Cap $61.1M
- Description
- Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...